rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    REPL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
      13h agoYahoo FinanceREPL
      How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss
      Nov 5Yahoo FinanceREPL
      Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
      Nov 2Yahoo FinanceREPL
      Is Replimune Group (REPL) Cheap Following Its Reduced Net Loss Results?
      Oct 29Yahoo FinanceREPL
      Replimune: 3 Key Takeaways for Long-Term Investors
      Oct 29Yahoo FinanceREPL
      Replimune Group, Inc. Q2 2027 Earnings Call Summary
      Oct 29Yahoo FinanceREPL
      Replimune (REPL) Q2 2027 Earnings Call Transcript
      Oct 28The Globe and MailREPL
      Replimune Group stock hits 52-week high at 16.39 USD
      Oct 28Investing.comREPL
      All eyes on Replimune earnings after melanoma drug launch
      Oct 28Investing.comREPL
      Earnings call transcript: Replimune Q2 2026 beats EPS as TUDRIQEV launch begins
      Oct 28Investing.comREPL
      Replimune Group Q2 2027 Earnings Call Transcript
      Oct 28BenzingaREPL
      Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
      Oct 28Yahoo FinanceREPL
      Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

      WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026. Listeners can register for the webcast via this link. Analysts wishing to participate in th

      Oct 22Yahoo FinanceREPL
      Replimune Group (REPL) Stock Looks Rich After A 141% Run
      Oct 17Yahoo FinanceREPL
      Replimune Group: A Hold Until TUDRIQEV’s Commercial Potential Becomes Clear (NASDAQ:REPL)
      Oct 13Seeking AlphaREPL
      Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
      Oct 9Yahoo FinanceREPL
      Cantor Fitzgerald reiterates Overweight on Replimune Group stock
      Oct 5Investing.comREPL
      Replimune launches melanoma therapy in US market
      Oct 1Investing.comREPL
      Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
      Oct 1Yahoo FinanceREPL
      Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

      ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now liveWOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination wi

      Oct 1Yahoo FinanceREPL
      REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky
      Sep 30MorningstarREPL
      REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
      Sep 24MorningstarREPL
      REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
      Sep 17MorningstarREPL
      Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
      Sep 16MorningstarREPL
      REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt
      Sep 10MorningstarREPL
      Replimune at cantor healthcare conference: careful launch, broad pipeline
      Sep 10Investing.comREPL
      REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
      Sep 9MorningstarREPL
      REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline
      Sep 3MorningstarREPL
      Replimune to Present at the Cantor Global Healthcare Conference 2026

      WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be availa

      Sep 3Yahoo FinanceREPL
      REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
      Sep 2MorningstarREPL
      Replimune Group stock hits 52-week high at 16.2 USD
      Sep 2Investing.comREPL
      REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
      Aug 26MorningstarREPL
      Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
      Aug 25MorningstarREPL
      Replimune Group stock hits 52-week high at 15.72 USD
      Aug 25Investing.comREPL
      Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action
      Aug 21MorningstarREPL

      This is the newest page. Registered accounts read further back.